Allergy Research Group, Inc. Reports Increased Sales for Third Quarter

ALAMEDA------Thursday November 10, 2005-----Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the third quarter ending September 30, 2005.

ALRG recorded total revenue of $3,835,014 for the quarter, up 3% from 2004. The increase of $111,613 is primarily due to increased sales to distributors and professional accounts.

Cost of sales increased $269,276 to $2,345,898 for the quarter ended September 30, 2005, compared to $2,076,622 for the quarter ended September 30, 2004. The increase in cost of sales is partially due to the increase in sales, but we also experienced increases in the cost of certain raw ingredients due to supply and demand pressures and increased product testing for quality assurance. The increase in costs was not passed on to our customers in order to preserve our customer base; therefore, gross profit margins decreased from approximately 44% for third quarter 2004 to approximately 39% for 2005. Based on the market pressures, we will forestall any significant price increases until 2006.

During the quarter ended September 30, 2005, the Company recorded net earnings of $244,274 as compared to net earnings of $354,336 for the same period in 2004. Net income decreased due to the decrease in profit margins and increased operating expenses.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Increased Sales for Second Quarter

ALAMEDA------August 12, 2005-----Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the second quarter ending June 30, 2005.

ALRG recorded total revenue of $3,981,676 for the quarter, up 4% from 2004. The increase of $149,316 is primarily due to increased sales to distributors and professional accounts.

Cost of sales increased $211,780 to $2,379,625 for the quarter ended June 30, 2005, compared to $2,167,845 for the quarter ended June 30, 2004. The increase in cost of sales is partially due to the increase in sales, but we also experienced increases in the cost of certain raw ingredients due to supply and demand pressures and the effect of the weakening U.S. dollar. The increase in costs was not passed on to our customers; therefore, gross profit margins decreased from approximately 43% for first quarter 2004 to approximately 40% for 2005. During the coming months we plan to recoup some of the increased cost through very selective price increases.

During the quarter ended June 30, 2005, the Company recorded net earnings of $324,710 as compared to net earnings of $344,962 for the same period in 2004. Ne t income decreased due to the decrease in profit margins and increased operating expenses .

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Increased Sales for First Quarter

ALAMEDA ---------May 16, 2005--------Allergy Research Group, Inc. (OTCBB:ALRG) announced financial results for the first quarter ending March 31, 2005.

ALRG recorded total revenue of $4,111,173 for the quarter, up 10% from 2004. The increase of $386,274 is primarily due to increased sales to distributors and professional accounts and continuing increased sales to our retail customers. We expect to continue to benefit from increased consumer awareness of the importance of nutritional supplements in one’s diet.

Cost of sales increased $288,766 to $2,423,385 for the quarter ended March 31, 2005, compared to $2,134,619 for the quarter ended March 31, 2004. The increase in cost of sales is partially due to the increase in sales, but we also experienced increases in certain raw ingredients. The increase in costs was not passed on to our customers; therefore gross profit margins decreased from approximately 43% for first quarter 2004 to approximately 41% for 2005.

During the quarter ended March 31, 2005, the Company recorded net earnings of $319,533 as compared to net earnings of $384,063 for the same period in 2004. The decrease primarily results from increased operating expenses related to our corporate office and manufacturing facility relocation.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department.

(top)

Allergy Research Group, Inc. Reports Record Earnings Before Tax For 2004

ALAMEDA, Calif.----March 31, 2005---- Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2004.

ALRG announces record earnings before tax of $2,213,397 for the year ended December 31, 2004, an increase of 12% compared to $1,972,163 for the same period ending December 31, 2003. Net income after tax for December 31, 2004 and 2003 was $1,282,736 and $1,643,770, respectively. Revenues also reached a record high of $15,136,592 for the year, up 11% from 2003. The increase in revenue of $1,483,736 is primarily due to effective marketing efforts, the introduction of new products and the continued growth in sales of existing products.

“Our continued effort to expand our product line with innovative hypoallergenic nutritional supplements has translated into increased sales, as well as, meeting our goal of providing quality products to our customers,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D.

Cost of sales increased $843,120 to $8,667,078 for the year ended December 31, 2004, compared to $7,823,958 for the year ended December 31, 2003. The increase corresponds to the increase in sales. Gross profit margins remained stable at approximately 43% for 2004 and 2003.

Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].

About Allergy Research Group, Inc.

Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.

# # #

Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.

(top)